Drug Approval | October 05, 2023
Alembic received 6 USFDA approvals during Q2FY24
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
This initiative encapsulates the essence of OPPI’s commitment towards enabling a healthier India
Time to combine innovation, access and technology to deliver positive patient outcomes
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Subscribe To Our Newsletter & Stay Updated
